[Management of pleural disease].
In view of the presentations in the First National Forum of Trainee Pneumologists, the present article focuses on infectious pleural effusions and on the study of possible markers of malignant disease in asbestos-exposed individuals. The yield of the distinct techniques for the diagnosis of tuberculous pleural effusion is assessed, with emphasis on analysis of sputum and pleural samples (fluid and tissue) for Mycobacteriumtuberculosis. The utility of adenosine deaminase (ADA) (in the absence of empyema, ADA > 70 U/l is diagnostic of tuberculous pleurisy, while values of less than 40 U/l exclude this diagnosis) and interferon gamma in pleural fluid (cut off: 3.7 Ul/ml) is also discussed. The management of complicated parapneumonic pleural effusions is stratified in four categories, depending on the anatomical and morphological (size and eventual presence of loculations), bacteriological (positivity or negativity of pleural fluid culture) and biochemical (pH/glucose) characteristics of the effusion. Finally, recently developed markers for the evaluation and follow-up of asbestos-exposed individuals are described, with special emphasis on serum determination of mesothelin levels, which seem highly promising as a marker of the development of mesothelioma in these cases. A multicenter study currently being performed in Spain found that soluble mesothelin-related protein (SMRP) levels higher than 0.55 nmol/L showed a sensitivity and specificity of 72% for the diagnosis of epithelial malignant mesothelioma.
Rodríguez-Panadero
Francisco
F
Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocío, Sevilla, España. frpanad@ono.com
Pérez
Myriam Aguilar
MA
Moya
Manuel Alejandro Muñoz
MA
Cruz
María Isabel Asensio
MI
D001194:Asbestos / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D003663:Decision Trees; D006801:Humans; D008654:Mesothelioma / Q000097:blood / Q000209:etiology; D010995:Pleural Diseases / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D010997:Pleural Neoplasms / Q000097:blood / Q000209:etiology
D015415:Biomarkers; D001194:Asbestos